A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens

Virulence

Volumn 5, Issue 1, 2014, Pages 226-235

  Wittebole, Xavier ^a   De Roock, Sophie ^b   Opal, Steven M ^c  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^c BROWN UNIVERSITY   (United States)

Author keywords

Bacteriophage therapy; Multidrug resistant pathogens; Phage therapy; Sepsis; Septic shock

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE THERAPY; BIOLOGICAL THERAPY; BURN; CENTRAL NERVOUS SYSTEM INFECTION; ECONOMIC ASPECT; GENE EXPRESSION; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; INTESTINE FLORA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SPECIES INVASION; BACTERIOPHAGE; CLASSIFICATION; METHODOLOGY; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT PATHOGENS; PATHOGENICITY; PHAGE THERAPY; SEPTIC SHOCK;

BACTERIOPHAGE THERAPY; MULTIDRUG RESISTANT PATHOGENS; PHAGE THERAPY; SEPSIS; SEPTIC SHOCK;

BACTERIAL INFECTIONS; BACTERIOPHAGES; BIOLOGICAL THERAPY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; SEPSIS;

EID: 84891713097     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.25991     Document Type: Review

References (117)

1. Sulakvelidze A. Bacteriophage: A new journal for the most ubiquitous organisms on Earth. Bacteriophage 2011; 1:1-2. PMID:21687529; http://dx.doi.org/10.4161/bact.1.1.15030.
2. Weinbauer MG. Ecology of prokaryotic viruses. FEMS Microbiol Rev 2004; 28:127-81. PMID:15109783; http://dx.doi.org/10.1016/j.femsre.2003.08.001.
3. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Int J Antimicrob Agents 2007; 30:118-28. PMID:17566713; http://dx.doi.org/10.1016/j.ijantimicag.2007.04.006.
4. d'Herelle F. Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 1931; 7:329-48. PMID:19311785.
5. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66-85. PMID:22334863; http://dx.doi.org/10.4161/bact.1.2.15845.
6. Chanishvili N. Phage therapy--history from Twort and d'Herelle through Soviet experience to current approaches. Adv Virus Res 2012; 83:3-40. PMID:22748807; http://dx.doi.org/10.1016/B978-0-12-394438-2.00001-3.
7. Eaton MD, Stanhope BJ. Bacteriophage therapy: review of the principle and results of the use of bacteriophage in the treatment of infection (I). J Am Med Assoc 1934; 103:1769-76; http://dx.doi.org/10.1001/jama.1934.72750490003007.
8. Eaton MD, Stanhope BJ. Bacteriophage therapy: review of the principle and results of the use of bacteriophage in the treatment of infection (II). J Am Med Assoc 1934; 103:1847-53; http://dx.doi.org/10.1001/jama.1934.72750500003009.
9. Eaton MD, Stanhope BJ. Bacteriophage therapy: review of the principle and results of the use of bacteriophage in the treatment of infection (III). J Am Med Assoc 1934; 103:1934-9; http://dx.doi.org/10.1001/jama.1934.72750510005009.
10. Hankin EH. L'action bactericide des eaux de la Jumna et du Gange sur le vibrion du cholera. Ann Inst Pasteur (Paris) 1896; 10:511-23.
11. Twort FW. An investigation on the nature of ultramicroscopic viruses. Lancet 1915; 186:1241-3; http://dx.doi.org/10.1016/S0140-6736(01)20383-3.
12. d'Herelle F. Sur un microbe invisible antagoniste des bacilles dysentériques. C R Acad Sci Paris 1917; 165:173-5.
13. Bordet J, Ciuca M. Remarques sur l'historique des recherches concernant la lyse microbienne transmissible. C R Soc Biol 1921; 84:745-7.
14. Duckworth DH. "Who discovered bacteriophage?" Bacteriol Rev 1976; 40:793-802. PMID:795414.
15. Summers WC. In the beginning... Bacteriophage 2011; 1:50-1. PMID:21687535; http://dx.doi.org/10.4161/bact.1.1.14070.
16. Bruynoghe R, Maisin J. Essais de thérapeutique au moyen du bacteriophage du Staphylocoque. Compt Rend Soc Biol 1921; 85:1120-1.
17. Northrop JH. Concentration and purification of bacteriophage. J Gen Physiol 1938; 21:335-66. PMID:19873054; http://dx.doi.org/10.1085/jgp.21.3.335.
18. Wollman E. Bacteriophage et processus similaire: Hérédité ou Infection? Bull Inst Pasteur Paris 1928; 26:1-14.
19. Muller HJ. Variation due to change in the individual gene. Am Nat 1922; 56:32-50; http://dx.doi.org/10.1086/279846.
20. Bordet J. Le problème de l'autolyse microbienne transmissible ou du bacteriophage. Ann Inst Pasteur (Paris) 1925; 39:711-63.
21. Sankaran N. The bacteriophage, its role in immunology: how Macfarlane Burnet's phage research shaped his scientific life. Studies in History and Phylosophy of Biological and Biomedical Sciences 2010; 41:367-75; http://dx.doi.org/10.1016/j.shpsc.2010.10.012
22. Burnet FM. The serological classification of Coli-Dysentery phages. J Pathol Bacteriol 1933; 36:307-18; http://dx.doi.org/10.1002/path.1700360212.
23. Pennazio S. The origin of phage virology. Riv Biol 2006; 99:103-29. PMID:16791793.
24. Schlesinger M. Zur frage der chemischen zusammensetzung des bakteriophagen. Biochem Z 1934; 273:306-11.
25. Ruska H. Die Sichtbarmachung der bakteriophagen Lyse im Übermikroskop. Naturwissenschaften 1940; 28:45-6; http://dx.doi.org/10.1007/BF01486931.
26. Kruger DH, Schneck P, Gelderblom HR. Helmut Ruska and the visualisation of viruses. Lancet 2000; 355:1713-7. PMID:10905259; http://dx.doi.org/10.1016/S0140-6736(00)02250-9.
27. Luria SE, Anderson TF. The identification and characterization of bacteriophages with the electron microscope. Proc Natl Acad Sci U S A 1942; 28:127-130.1. PMID:16588529; http://dx.doi.org/10.1073/pnas.28.4.127.
28. Luria SE, Delbrück M, Anderson TF. Electron Microscope Studies of Bacterial Viruses. J Bacteriol 1943; 46:57-77. PMID:16560678.
29. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128:307-18. PMID:7042903.
30. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129:2659-75. PMID:6355391.
31. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009; 18:237-8, 240-3. PMID:19661847.
32. Adhya S, Black L, Friedman D, Hatfull G, Kreuzer K, Merril C, Oppenheim A, Rohwer F, Young R. 2004 ASM Conference on the New Phage Biology: the 'Phage Summit'. Mol Microbiol 2005; 55:1300-14. PMID:15720541; http://dx.doi.org/10.1111/j.1365-2958.2005.04509.x
33. Ackerman HW. Obituary - Hansjürgen Raettig - Collector of bacteriophages references. BEG news 2000; 3:5 (http://phage.org/2000)
34. Ackermann HW. Who went into phage research? Bacteriophage 2012; 2:55-9. PMID:22666657; http://dx.doi.org/10.4161/bact.18680.
35. Ackermann HW, Prangishvili D. Prokaryote viruses studied by electron microscopy. Arch Virol 2012; 157:1843-9. PMID:22752841; http://dx.doi.org/10.1007/s00705-012-1383-y
36. Deghorain M, Van Melderen L. The Staphylococci phages family: an overview. Viruses 2012; 4:3316-35. PMID:23342361; http://dx.doi.org/10.3390/v4123316.
37. Ceyssens PJ, Lavigne R. Bacteriophages of Pseudomonas. Future Microbiol 2010; 5:1041-55. PMID:20632804; http://dx.doi.org/10.2217/fmb.10.66.
38. Ackermann HW. Bacteriophages: characteristics and 1st stages of a classification. Pathol Biol (Paris) 1969; 17:1003-24. PMID:4907644.
39. Ackermann HW. Bacteriophage taxonomy in 1987. Microbiol Sci 1987; 4:214-8. PMID:3153614.
40. Ackermann HW. Frequency of morphological phage descriptions in 1995. Arch Virol 1996; 141:209-18. PMID:8634015; http://dx.doi.org/10.1007/BF01718394.
41. Rohwer F, Edwards R. The Phage Proteomic Tree: a genome-based taxonomy for phage. J Bacteriol 2002; 184:4529-35. PMID:12142423; http://dx.doi.org/10.1128/JB.184.16.4529-4535.2002.
42. Fauquet CM, Pringle CR. Abbreviations for bacterial and fungal virus species names. Arch Virol 2000; 145:197-203. PMID:10664418; http://dx.doi.org/10.1007/s007050050017.
43. Drulis-Kawa Z, Majkowska-Skrobek G, Maciejewska B, Delattre AS, Lavigne R. Learning from bacteriophages -advantages and limitations of phage and phage-encoded protein applications. Curr Protein Pept Sci 2012; 13:699-722. PMID:23305359; http://dx.doi.org/10.2174/138920312804871193.
44. Chatterjee S, Rothenberg E. Interaction of bacteriophage l with its E. coli receptor, LamB. Viruses 2012; 4:3162-78. PMID:23202520; http://dx.doi.org/10.3390/v4113162.
45. Canchaya C, Fournous G, Chibani-Chennoufi S, Dillmann ML, Brüssow H. Phage as agents of lateral gene transfer. Curr Opin Microbiol 2003; 6:417-24. PMID:12941415; http://dx.doi.org/10.1016/S1369-5274(03)00086-9.
46. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 2009; 106:4629-34. PMID:19255432; http://dx.doi.org/10.1073/pnas.0800442106.
47. Edgar R, Friedman N, Molshanski-Mor S, Qimron U. Reversing bacterial resistance to antibiotics by phagemediated delivery of dominant sensitive genes. Appl Environ Microbiol 2012; 78:744-51. PMID:22113912; http://dx.doi.org/10.1128/AEM.05741-11.
48. Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010; 36(Suppl 2):S50-4. PMID:21129924; http://dx.doi.org/10.1016/j.ijantimicag.2010.11.014.
49. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. N Engl J Med 2009; 360:439-43. PMID:19179312; http://dx.doi.org/10.1056/NEJMp0804651.
50. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, et al.; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71. PMID:17940231; http://dx.doi.org/10.1001/jama.298.15.1763.
51. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013; 11:297-308. PMID:23458769; http://dx.doi.org/10.1586/eri.13.12.
52. Morales E, Cots F, Sala M, Comas M, Belvis F, Riu M, Salvadó M, Grau S, Horcajada JP, Montero MM, et al. Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Serv Res 2012; 12:122. PMID:22621745; http://dx.doi.org/10.1186/1472-6963-12-122.
53. Selgelid MJ. Ethics and drug resistance. Bioethics 2007; 21:218-29. PMID:17845480; http://dx.doi.org/10.1111/j.1467-8519.2006.00542.x
54. Aiello AE, King NB, Foxman B. Ethical conflicts in public health research and practice: antimicrobial resistance and the ethics of drug development. Am J Public Health 2006; 96:1910-4. PMID:17018817; http://dx.doi.org/10.2105/AJPH.2005.077214.
55. Gravitz L. Turning a new phage. Nat Med 2012; 18:1318-20. PMID:22961150; http://dx.doi.org/10.1038/nm0912-1318.
56. World Medical Association Statement on Resistance to antimicrobial agents www.wma.net/e/policy/a19htm
57. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, Cars O; ECDC-EMA Working Group. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat 2011; 14:118-24. PMID:21435939; http://dx.doi.org/10.1016/j. drup.2011.02.003.
58. Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol 2011; 14:564-9. PMID:21873107; http://dx.doi.org/10.1016/j.mib.2011.08.002.
59. Mahony J, McAuliffe O, Ross RP, van Sinderen D. Bacteriophages as biocontrol agents of food pathogens. Curr Opin Biotechnol 2011; 22:157-63. PMID:21115341; http://dx.doi.org/10.1016/j.copbio.2010.10.008.
60. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virol J 2012; 9:9. PMID:22234269; http://dx.doi.org/10.1186/1743-422X-9-9.
61. Atterbury RJ. Bacteriophage biocontrol in animals and meat products. Microb Biotechnol 2009; 2:601-12. PMID:21255295; http://dx.doi.org/10.1111/j.1751-7915.2009.00089.x
62. Jain P, Hartman TE, Eisenberg N, O'Donnell MR, Kriakov J, Govender K, Makume M, Thaler DS, Hatfull GF, Sturm AW, et al. φ(2)GFP10, a highintensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples. J Clin Microbiol 2012; 50:1362-9. PMID:22278833; http://dx.doi.org/10.1128/JCM.06192-11.
63. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 2003; 187:613-24. PMID:12599078; http://dx.doi.org/10.1086/374001.
64. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002; 70:204-10. PMID:11748184; http://dx.doi.org/10.1128/IAI.70.1.204-210.2002.
65. Vinodkumar CS, Neelagund YF, Kalsurmath S. Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. J Commun Dis 2005; 37:18-29. PMID:16637396.
66. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Reed E, Ding L, Gong J, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2006; 17:309-17. PMID:16391831.
67. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, Sun Z, Tao D, Ding L, Reed E, et al. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum β-lactamase-producing Escherichia coli bacteremia. Int J Mol Med 2006; 17:347-55. PMID:16391836.
68. Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brüssow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 2004; 48:2558-69. PMID:15215109; http://dx.doi.org/10.1128/AAC.48.7.2558-2569.2004.
69. Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005; 49:2874-8. PMID:15980363; http://dx.doi.org/10.1128/AAC.49.7.2874-2878.2005.
70. Sarker SA, McCallin S, Barretto C, Berger B, Pittet AC, Sultana S, Krause L, Huq S, Bibiloni R, Bruttin A, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012; 434:222-32. PMID:23102968; http://dx.doi.org/10.1016/j.virol.2012.09.002.
71. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 2012; 56:3568-75. PMID:22491690; http://dx.doi.org/10.1128/AAC.06330-11.
72. Alisky J, Iczkowski K, Rapoport A, Troitsky N. Bacteriophages show promise as antimicrobial agents. J Infect 1998; 36:5-15. PMID:9515662; http://dx.doi.org/10.1016/S0163-4453(98)92874-2.
73. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G. Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 2009; 10:766-74. PMID:19649921.
74. Azeredo J, Sutherland IW. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 2008; 9:261-6. PMID:18691087; http://dx.doi.org/10.2174/138920108785161604.
75. Weber-Dabrowska B, Zimecki M, Mulczyk M. Effective phage therapy is associated with normalization of cytokine production by blood cell cultures. Arch Immunol Ther Exp (Warsz) 2000; 48:31-7. PMID:10722229.
76. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górski A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med 2009; 9:303-12. PMID:19350363; http://dx.doi.org/10.1007/s10238-009-0044-2.
77. Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Fortuna W, Letkiewicz S, Szufnarowski K, Pawełczyk Z, Rogóz P, Kłak M, Wojtasik E, et al. Clinical aspects of phage therapy. Adv Virus Res 2012; 83:73-121. PMID:22748809; http://dx.doi.org/10.1016/B978-0-12-394438-2.00003-7.
78. Weber-Dabrowska B, Zimecki M, Mulczyk M, Górski A. Effect of phage therapy on the turnover and function of peripheral neutrophils. FEMS Immunol Med Microbiol 2002; 34:135-8. PMID:12381464; http://dx.doi.org/10.1111/j.1574-695X.2002.tb00614.x
79. Górski A, Miedzybrodzki R, Borysowski J, Dabrowska K, Wierzbicki P, Ohams M, Korczak-Kowalska G, Olszowska-Zaremba N, Łusiak-Szelachowska M, Kłak M, et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 2012; 83:41-71. PMID:22748808; http://dx.doi.org/10.1016/B978-0-12-394438-2.00002-5.
80. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, Górski A. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy Hig Med Dosw (Online) 2007; 61:461-5. PMID:17679835.
81. Merabishvili M, De Vos D, Verbeken G, Kropinski AM, Vandenheuvel D, Lavigne R, Wattiau P, Mast J, Ragimbeau C, Mossong J, et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One 2012; 7:e52709. PMID:23285164; http://dx.doi.org/10.1371/journal.pone.0052709.
82. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4:e4944. PMID:19300511; http://dx.doi.org/10.1371/journal.pone.0004944.
83. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, et al. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 2011; 28:934-7. PMID:21063753; http://dx.doi.org/10.1007/s11095-010-0313-5.
84. Jończyk E, Kłak M, Miedzybrodzki R, Górski A. The influence of external factors on bacteriophages--review. Folia Microbiol (Praha) 2011; 56:191-200. PMID:21625877; http://dx.doi.org/10.1007/s12223-011-0039-8.
85. Brabban AD, Hite E, Callaway TR. Evolution of foodborne pathogens via temperate bacteriophage-mediated gene transfer. Foodborne Pathog Dis 2005; 2:287-303. PMID:16366852; http://dx.doi.org/10.1089/fpd.2005.2.287.
86. O'Shea YA, Boyd EF. Mobilization of the Vibrio pathogenicity island between Vibrio cholerae isolates mediated by CP-T1 generalized transduction. FEMS Microbiol Lett 2002; 214:153-7. PMID:12351223; http://dx.doi.org/10.1111/j.1574-6968.2002.tb11339.x
87. Maiques E, Ubeda C, Tormo MA, Ferrer MD, Lasa I, Novick RP, Penadés JR. Role of staphylococcal phage and SaPI integrase in intra-and interspecies SaPI transfer. J Bacteriol 2007; 189:5608-16. PMID:17545290; http://dx.doi.org/10.1128/JB.00619-07
88. Hatfull GF. Bacteriophage genomics. Curr Opin Microbiol 2008; 11:447-53. PMID:18824125; http://dx.doi.org/10.1016/j.mib.2008.09.004.
89. Ackermann HW, Kropinski AM. Curated list of prokaryote viruses with fully sequenced genomes. Res Microbiol 2007; 158:555-66. PMID:17889511; http://dx.doi.org/10.1016/j.resmic.2007.07.006.
90. Goodridge LD. Designing phage therapeutics. Curr Pharm Biotechnol 2010; 11:15-27. PMID:20214605; http://dx.doi.org/10.2174/138920110790725348.
91. Dabrowska K, Switała-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A. Bacteriophage penetration in vertebrates. J Appl Microbiol 2005; 98:7-13. PMID:15610412; http://dx.doi.org/10.1111/j.1365-2672.2004.02422.x
92. Liu M, Deora R, Doulatov SR, Gingery M, Eiserling FA, Preston A, Maskell DJ, Simons RW, Cotter PA, Parkhill J, et al. Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage. Science 2002; 295:2091-4. PMID:11896279; http://dx.doi.org/10.1126/science.1067467.
93. Riede I, Eschbach ML. Evidence that TraT interacts with OmpA of Escherichia coli. FEBS Lett 1986; 205:241-5. PMID:3527751; http://dx.doi.org/10.1016/0014-5793(86)80905-X
94. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 2010; 11:69-86. PMID:20214609; http://dx.doi.org/10.2174/138920110790725401.
95. Stafford N. Switzerland is to fund complementary therapies for six years while effectiveness is evaluated. BMJ 2011; 342:d819. PMID:21300707; http://dx.doi.org/10.1136/bmj.d819.
96. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 1992; 37:258-61. PMID:1404324; http://dx.doi.org/10.1099/00222615-37-4-258.
97. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 1996; 93:3188-92. PMID:8622911; http://dx.doi.org/10.1073/pnas.93.8.3188.
98. Barrow P, Lovell M, Berchieri A Jr. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin Diagn Lab Immunol 1998; 5:294-8. PMID:9605979.
99. Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 2005; 49:1220-1. PMID:15728933; http://dx.doi.org/10.1128/AAC.49.3.1220-1221.2005.
100. Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, Uchiyama J, Sakurai S, Matsuzaki S, Imai S, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother 2007; 51:446-52. PMID:17116686; http://dx.doi.org/10.1128/AAC.00635-06.
101. Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol 2008; 51:360-6. PMID:18723958; http://dx.doi.org/10.4103/0377-4929.42511.
102. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 2010; 201:1096-104. PMID:20196657; http://dx.doi.org/10.1086/651135.
103. Sunagar R, Patil SA, Chandrakanth RK. Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Res Microbiol 2010; 161:854-60. PMID:20868746; http://dx.doi.org/10.1016/j.resmic.2010.09.011.
104. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother 2011; 55:1358-65. PMID:21245450; http://dx.doi.org/10.1128/AAC.01123-10.
105. Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J Med Microbiol 2011; 60:205-10. PMID:20965914; http://dx.doi.org/10.1099/jmm.0.018580-0.
106. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 2011; 6:e16963. PMID:21347240; http://dx.doi.org/10.1371/journal.pone.0016963.
107. Tóthová L, Celec P, Bábíčková J, Gajdošová J, Al-Alami H, Kamodyova N, Drahovská H, Liptáková A, Turňa J, Hodosy J. Phage therapy of Cronobacter-induced urinary tract infection in mice. Med Sci Monit 2011; 17:BR173-8. PMID:21709627; http://dx.doi.org/10.12659/MSM.881844.
108. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012; 3:e00029-12. PMID:22396480; http://dx.doi.org/10.1128/mBio.00029-12.
109. Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implantrelated infections: an experimental study. J Bone Joint Surg Am 2013; 95:117-25. PMID:23324958; http://dx.doi.org/10.2106/JBJS.K.01135.
110. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66-85. PMID:22334863; http://dx.doi.org/10.4161/bact.1.2.15845.
111. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 1987; 35:569-83. PMID:3455647.
112. Chanishvili N, Chanishvili T, Tediashvili M, Parrow PA. Phages and their applications against drug resistant bacteria. J Chem Technol Biotechnol 2001; 76:689-99; http://dx.doi.org/10.1002/jctb.438.
113. Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45:649-59. PMID:11181338; http://dx.doi.org/10.1128/AAC.45.3.649-659.2001.
114. Summers WC. Bacteriophage therapy. Annu Rev Microbiol 2001; 55:437-51. PMID:11544363; http://dx.doi.org/10.1146/annurev.micro.55.1.437.
115. Sulakvelidze A, Kutter E. Bacteriophage therapy. In Kutter E, Sulakvelidze editors. Bacteriophage biology and applications. Boca Raton, Fl: CRC Press; 2005 p381-436.
116. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34:349-57. PMID:19673983; http://dx.doi.org/10.1111/j.1749-4486.2009.01973.x
117. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009; 4:e4944. PMID:19300511; http://dx.doi.org/10.1371/journal.pone.0004944